Sam Brusco, Associate Editor09.21.22
Biolectronic medicine company electroCore has been granted four U.S. patents for its non-invasive vagus nerve stimulation (nVNS) and other technologies.
“We are pleased to be granted these four new patents by the USPTO, which strengthen our intellectual patent portfolio,” Dan Goldberger, CEO of electroCore told the press. “These new patents support our mobile connectivity platform, by using mobile devices coupled with a stimulator to deliver nVNS therapy. The addition of these patents underscores our commitment to advancing therapy beyond those who suffer from migraines and cluster headaches, and we look forward to continuing to explore the role of nVNS for various conditions.”
- U.S. Patent No. 11,406,825 entitled “Mobile Phone for Treating a Patient with Dementia” relates to nVNS therapies for neurodegenerative diseases like Alzheimer’s or dementia with a stimulator coupled to a mobile device.
- U.S. Patent No. 11,432,760 entitled “Devices and Methods for Remote Therapy and Patient Monitoring” relates to nVNS including a stimulator coupled to a mobile device, where the stimulator transmits data including position of electrodes one the skin surface relative to the target nerve.
- U.S. Patent No. 11,439,818 entitled “Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and Other Functional Gastrointestinal Disorders” relates to nVNS therapies for post-operative ileus.
- U.S. Patent No. 11,446,491 entitled “Stimulator for Use with a Mobile Device” is another in the series of patents related to nerve stimulators with mobile devices. It includes device and method claims to generate an electrical impulse using a stimulator coupled to a mobile device and applying the impulse through an outer skin surface to a targeted site.
“We are pleased to be granted these four new patents by the USPTO, which strengthen our intellectual patent portfolio,” Dan Goldberger, CEO of electroCore told the press. “These new patents support our mobile connectivity platform, by using mobile devices coupled with a stimulator to deliver nVNS therapy. The addition of these patents underscores our commitment to advancing therapy beyond those who suffer from migraines and cluster headaches, and we look forward to continuing to explore the role of nVNS for various conditions.”